A Candidate Ac3-S-LPS Vaccine Against S. flexneri 1b, 2a, 3a, 6, and Y Activates Long-Lived Systemic and Mucosal Immune Responses in Healthy Volunteers: Results of an Open-Label, Randomized Phase 2 Clinical Trial
the tolerability of PLVF and the pronounced humoral immune response allow us to proceed to the phase 3 clinical trial stage.
Authors
- Victor V. Romanenko
- M.E. Golovina
- Alexander L. Kovalchuk (ORCID: https://orcid.org/0000-0003-2761-0442)
- Vladimir A. Ledov
- Biana I. Alkhazova
- Petr G. Aparin
Institutions
- InSysBio (Russia) (RU)
- Federal Medical-Biological Agency (RU)
Publication Details
- Journal
- Vaccines
- Published
- 2025-02-20
- DOI
- https://doi.org/10.3390/vaccines13030209
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00